🍽️ butacaine,(prescription)

AI Engines For more Details: PerplexityKagi LabsYou

Check for interactions on Supp.AI   |   πŸ“š PubMed Citations   |   βš—οΈ Compensation for antibiotic usage

Data Contradictions β€” Limits of Certainity

Impacted of butacaine,(prescription) On Probiotics

Rank Probiotic Impact
species Akkermansia muciniphila Reduces

Bacteria Impacted by butacaine,(prescription)

We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.

πŸ§™?

Taxonomy Rank Effect Citations Notation
Akkermansia genus Decreases 👪 Source Study
Lacrimispora genus Decreases 👪 Source Study
Enterocloster genus Decreases 👪 Source Study
Thomasclavelia genus Decreases 👪 Source Study
Agathobacter genus Decreases 👪 Source Study
Mediterraneibacter genus Decreases 👪 Source Study
Eggerthella genus Decreases 👪 Source Study
Streptococcus genus Decreases 👪 Source Study
Bilophila genus Decreases 👪 Source Study High Level Cause Brain Fog(Cognitive impairment)
unclassified Robinsoniella no rank Decreases ⚗️ Source Study
unclassified Fusobacterium no rank Decreases ⚗️ Source Study
unclassified Negativicoccus no rank Decreases ⚗️ Source Study
Eggerthellales order Decreases ⚗️ Source Study
Akkermansia muciniphila species Decreases 📓 Source Study
Lacrimispora saccharolytica species Decreases 📓 Source Study
Enterocloster bolteae species Decreases 📓 Source Study
Thomasclavelia ramosa species Decreases 📓 Source Study
Anaerofustis stercorihominis species Decreases ⚗️ Source Study
Asaccharospora irregularis species Decreases ⚗️ Source Study
Negativicoccus sp. S5-A15 species Decreases ⚗️ Source Study
Paraprevotella clara species Decreases ⚗️ Source Study
Slackia sp. NATTS species Decreases ⚗️ Source Study
Agathobacter rectalis species Decreases 📓 Source Study
Pseudoflavonifractor capillosus species Decreases ⚗️ Source Study
[Collinsella] massiliensis species Decreases ⚗️ Source Study
Parvibacter caecicola species Decreases ⚗️ Source Study
[Ruminococcus] gnavus species Decreases 📓 Source Study
[Ruminococcus] torques species Decreases 📓 Source Study
Eggerthella lenta species Decreases 📓 Source Study
Streptococcus salivarius species Decreases 📓 Source Study Infectious bacteria
Bilophila wadsworthia species Decreases 📓 Source Study
Coriobacterineae suborder Decreases ⚗️ Source Study
Chlamydiae/Verrucomicrobia group superphylum Decreases ⚗️ Source Study

Impact of butacaine,(prescription) on Conditions from US National Library of Medicine

A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.

We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive   X|increases + Y|decrease = Negative.

Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.

Condition Positive Impact Negative Impact Benefit Ratio Impact
Abdominal Aortic Aneurysm 0 0
ADHD 0.1 0 0
Allergic Rhinitis (Hay Fever) 0.1 0.1
Allergies 0 0.6 0
Alzheimer's disease 0.3 0.3 0
Amyotrophic lateral sclerosis (ALS) Motor Neuron 0.8 0.6 0.33
Ankylosing spondylitis 0 0.1 0
Anorexia Nervosa 0.1 -0.1
Antiphospholipid syndrome (APS) 0 0 0
Asthma 0.1 0.8 -7
Atherosclerosis 0.3 -0.3
Atrial fibrillation 0.1 0 0
Autism 1.4 1 0.4
Barrett esophagus cancer 0 0
Bipolar Disorder 0 0 0
Carcinoma 0.1 0.1
Celiac Disease 0 0.3 0
Cerebral Palsy 0.3 0.3
Chronic Fatigue Syndrome 0.6 0 0
Chronic Kidney Disease 0.2 0.1 1
Chronic Obstructive Pulmonary Disease (COPD) 0.1 0.1
Chronic Urticaria (Hives) 0 0.6 0
Coagulation / Micro clot triggering bacteria 0 0 0
Colorectal Cancer 0 0.1 0
Coronary artery disease 0.2 0.2
COVID-19 0.9 1.3 -0.44
Crohn's Disease 0.4 0.4 0
deep vein thrombosis 0 0
Depression 1 1.1 -0.1
Dermatomyositis 0 0
Eczema 0.1 0.1 0
Endometriosis 0 0
Epilepsy 0.3 0.8 -1.67
Fibromyalgia 0.2 0.2
Functional constipation / chronic idiopathic constipation 0.1 -0.1
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus 0 0
Generalized anxiety disorder 0.1 0.1
Glioblastoma 0 0
Halitosis 0 0
Hashimoto's thyroiditis 0.4 0 0
Hidradenitis Suppurativa 0 0
Histamine Issues,Mast Cell Issue, DAO Insufficiency 0.1 0.1 0
hypercholesterolemia (High Cholesterol) 0.6 -0.6
hyperglycemia 0.8 -0.8
Hyperlipidemia (High Blood Fats) 0.3 0.3
hypersomnia 0 0
hypertension (High Blood Pressure 0.3 0.3 0
Hypothyroidism 0 0
Hypoxia 0.3 0.3
IgA nephropathy (IgAN) 0.1 -0.1
Inflammatory Bowel Disease 0.4 1.1 -1.75
Insomnia 0 0
Irritable Bowel Syndrome 0.6 0.6 0
Liver Cirrhosis 0.3 0.3 0
Long COVID 1 0.1 9
Lung Cancer 0.6 -0.6
ME/CFS with IBS 0.3 0.3
ME/CFS without IBS 0.3 0.3
Metabolic Syndrome 0.4 0.9 -1.25
Mood Disorders 1.6 1.1 0.45
multiple chemical sensitivity [MCS] 0.3 0.3
Multiple Sclerosis 1 0.2 4
Multiple system atrophy (MSA) 0.8 0.8
Neuropathy (all types) 0.3 0.3
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic 0 0.7 0
Obesity 0.5 0.9 -0.8
obsessive-compulsive disorder 0 0.8 0
Osteoarthritis 0.3 0.3
Osteoporosis 0 0.6 0
pancreatic cancer 0 0
Parkinson's Disease 0.9 0.1 8
Polycystic ovary syndrome 0.3 -0.3
Psoriasis 0.3 0.6 -1
rheumatoid arthritis (RA),Spondyloarthritis (SpA) 0.4 0.4
Rosacea 0.1 0.1
Schizophrenia 0.6 0.6
scoliosis 0 0
Sjögren syndrome 0 0.1 0
Sleep Apnea 0 0
Small Intestinal Bacterial Overgrowth (SIBO) 0 0
Stress / posttraumatic stress disorder 0.3 0.6 -1
Systemic Lupus Erythematosus 0.2 0.2
Tourette syndrome 0.3 0.3
Type 1 Diabetes 0 0 0
Type 2 Diabetes 0.4 0.9 -1.25
Ulcerative colitis 0 0.9 0
Unhealthy Ageing 0.5 0.4 0.25

This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.

Copyright 2016-2023 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β€―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.

Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.


The awesome web hosting site that we use. Try it if you need to host (or unhappy with current provider)